Syngene International Ltd. – FDA 483, Feb 20, 2025
An FDA inspection of Syngene International Ltd. in Bengaluru, India, revealed significant deficiencies in their API, Drug Substance, and Finished Drug Product manufacturing operations. Observations included inadequate vendor qualification for critical consumables, a deficient environmental monitoring program, and failures in investigating nonconformances. Additionally, issues were noted with the security and management of controlled documents and the cleanability of classified manufacturing areas.
ID · 0399825e-1d13-4206-b368-94c7a473c188
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.